PMID- 15615560
OWN - NLM
STAT- MEDLINE
DCOM- 20050510
LR  - 20161124
IS  - 1526-6028 (Print)
IS  - 1526-6028 (Linking)
VI  - 11
IP  - 6
DP  - 2004 Dec
TI  - Transcatheter transplantation of autologous skeletal myoblasts in postinfarction 
      patients with severe left ventricular dysfunction.
PG  - 695-704
AB  - PURPOSE: To report a case-controlled safety and feasibility study of 
      transcatheter transplantation of autologous skeletal myoblasts as a stand-alone 
      procedure in patients with ischemic heart failure. METHODS: Six men (mean age 
      66.2+/-7.2 years) were eligible for transcatheter transplantation of autologous 
      skeletal myoblasts cultured from quadriceps muscle biopsies. Six other men (mean 
      age 65.7+/-6.3 years) were selected as matched controls (no muscle biopsies). A 
      specially designed injection catheter was advanced through a femoral sheath into 
      the left ventricle cavity, where myoblasts in solution (0.2 mL/injection) were 
      injected into the myocardium via a 25-G needle. At baseline and in follow-up, 
      both groups underwent Holter monitoring, a 6-minute walk test, New York Heart 
      Association (NYHA) class determination, and echocardiography with dobutamine 
      challenge. RESULTS: Skeletal myoblast transplantation was technically successful 
      in all 6 patients with no complications; 19+/-10 injections were performed per 
      patient (210 x 10(6)+/-150 x 10(6) cells implanted per patient). Left ventricular 
      ejection fraction (LVEF) rose from 24.3%+/-6.7% at baseline to 32.2%+/-10.2% at 
      12 months after myoblast implantation (p=0.02 versus baseline and p<0.05 versus 
      controls); in matched controls, LVEF decreased from 24.7%+/-4.6% to 21.0%+/-4.0% 
      (p=NS). Walking distance and NYHA functional class were significantly improved at 
      1 year (p=0.02 and p=0.001 versus baseline, respectively), whereas matched 
      controls were unchanged. CONCLUSIONS: Transcatheter transplantation of autologous 
      skeletal myoblasts for severe left ventricular dysfunction in postinfarction 
      patients is feasible, safe, and promising. Scrutiny with randomized, 
      double-blinded, multicenter trials appears warranted.
FAU - Ince, Huseyin
AU  - Ince H
AD  - Division of Cardiology/Angiology and Department of Internal Medicine at the 
      University Hospital Rostock, Germany.
FAU - Petzsch, Michael
AU  - Petzsch M
FAU - Rehders, Tim C
AU  - Rehders TC
FAU - Chatterjee, Tushar
AU  - Chatterjee T
FAU - Nienaber, Christoph A
AU  - Nienaber CA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Endovasc Ther
JT  - Journal of endovascular therapy : an official journal of the International 
      Society of Endovascular Specialists
JID - 100896915
SB  - IM
MH  - Aged
MH  - *Cardiac Catheterization
MH  - Case-Control Studies
MH  - Cell Transplantation/methods
MH  - Chi-Square Distribution
MH  - Coronary Angiography
MH  - Feasibility Studies
MH  - Follow-Up Studies
MH  - Graft Rejection
MH  - Graft Survival
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myoblasts/*transplantation
MH  - Myocardial Infarction/complications/diagnostic imaging/*therapy
MH  - Probability
MH  - Risk Assessment
MH  - Severity of Illness Index
MH  - Statistics, Nonparametric
MH  - Transplantation, Autologous
MH  - Treatment Outcome
MH  - Ventricular Dysfunction, Left/complications/diagnosis/*therapy
EDAT- 2004/12/24 09:00
MHDA- 2005/05/11 09:00
CRDT- 2004/12/24 09:00
PHST- 2004/12/24 09:00 [pubmed]
PHST- 2005/05/11 09:00 [medline]
PHST- 2004/12/24 09:00 [entrez]
AID - 04-1386R [pii]
AID - 10.1583/04-1386R.1 [doi]
PST - ppublish
SO  - J Endovasc Ther. 2004 Dec;11(6):695-704. doi: 10.1583/04-1386R.1.